Alvotech (ALVO) Net Equity Issued and Repurchased (2023 - 2025)
Alvotech's (ALVO) quarterly Net Equity Issued and Repurchased came in at -$82.4 million in Q3 2025, up 45.18% YoY from -$56.8 million in Q3 2024, and down 48.28% on a QoQ basis from -$55.6 million in Q2 2025.
Alvotech (ALVO) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Alvotech (ALVO) has 3 years of Net Equity Issued and Repurchased data on file, last reported at -$82.4 million in Q3 2025.
- Quarterly Net Equity Issued and Repurchased rose 45.18% year-over-year to -$82.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $150.5 million (up 1257.6% YoY) and the FY2023 annual result came in at $136.9 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased declined to -$82.4 million in Q3 2025, from -$55.6 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $150.5 million in Q4 2024 to a low of -$150.3 million in Q3 2024.
- A 3-year average of $30.5 million and a median of $419660.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased tumbled 99.69% — and 2025, when it soared 32795.44%.
- Tracing ALVO's Net Equity Issued and Repurchased over 3 years: stood at $136.9 million in 2023, then advanced by 9.92% to $150.5 million in 2024, then sank by 154.77% to -$82.4 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at -$82.4 million (Q3 2025), -$55.6 million (Q2 2025), and $138.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alvotech | 1.23 Bn | 1.23 Bn | 5.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -82.40 Mn |
| Sep 30, 2025 | -82.40 Mn |
| Jun 30, 2025 | -55.57 Mn |
| Jun 30, 2025 | -55.57 Mn |
| Mar 31, 2025 | 138.05 Mn |
| Mar 31, 2025 | 138.05 Mn |
| Dec 31, 2024 | 150.45 Mn |
| Dec 31, 2024 | 150.45 Mn |
| Sep 30, 2024 | -150.30 Mn |
| Sep 30, 2024 | -150.30 Mn |
| Mar 31, 2024 | 419,660.00 |
| Mar 31, 2024 | 419,660.00 |
| Dec 31, 2023 | 136.88 Mn |
| Dec 31, 2023 | 136.88 Mn |
| Jun 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Mar 31, 2023 | 136.88 Mn |
| Mar 31, 2023 | 136.88 Mn |